器官移植免疫抑制患者皮肤鳞状细胞癌第二肿瘤、转移及死亡风险研究
结果显示,OTRs发生第二cSCC、转移及死于cSCC的调整后风险分别增加4.3倍、1.5倍和5.5倍,但两组多数患者死于非cSCC原因。
要点
- OTRs发生第二cSCC的率为250.6/1000人年,非OTRs为30.9/1000人年,调整后风险增加4.3倍。
- OTRs死于cSCC的率为5.4/1000人年,非OTRs为1.7/1000人年,调整后风险增加5.5倍。
- OTRs转移率为4.8/1000人年,非OTRs为2.8/1000人年,调整后风险增加1.5倍。
核心结论
- OTRs的cSCC患者发生第二cSCC、转移及死于cSCC的风险显著高于非OTRs,但两组多数患者死于非cSCC原因。
主要发现
- 第二cSCC率:非OTRs为30.9/1000人年(95%CI 30.2-31.6),OTRs为250.6/1000人年(95%CI 232.2-270.1),调整后OTRs风险增加4.3倍。
- 转移率:非OTRs为2.8/1000人年(95%CI 2.6-3.0),OTRs为4.8/1000人年(95%CI 3.4-6.7),调整后OTRs风险增加1.5倍。
- 死于cSCC率:非OTRs为1.7/1000人年(95%CI 1.5-1.8),OTRs为5.4/1000人年(95%CI 3.9-7.4),调整后OTRs风险增加5.5倍。
临床怎么用
- 研究结果对cSCC患者的随访计划及皮肤癌诊疗服务规划具有参考价值。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cutaneous squamous cell carcinoma (cSCC) may occur with multiple primary tumors, metastasize, and cause death both in immunocompetent and immunosuppressed patients. OBJECTIVE: To study the rates of second cSCC, metastasis, and death from cSCC in patients with and without organ transplant-associated immunosuppressive treatment. DESIGN, SETTING, AND PARTICIPANTS: This population-based, nationwide cohort study used Cancer Registry of Norway data from 47 992 individuals diagnosed with cSCC at 18 years or older between January 1, 1968, and December 31, 2020. Data were analyzed between November 24, 2021, and November 15, 2022. EXPOSURES: Receipt of a solid organ transplant at Oslo University Hospital between 1968 and 2012 followed by long-term immunosuppressive treatment. MAIN OUTCOMES AND MEASURES: Absolute rates of second cSCC, metastasis, and death from cSCC were calculated per 1000 person-years with 95% CIs. Hazard ratios (HRs) estimated using Cox proportional hazard regression were adjusted for age, sex, and year of first cSCC diagnosis. RESULTS: The study cohort comprised 1208 organ transplant recipients (OTRs) (median age, 66 years [range, 27-89 years]; 882 men [73.0%] and 326 women [27.0%]) and 46 784 non-OTRs (median age, 79 years [range, 18-106 years]; 25 406 men [54.3%] and 21 378 women [45.7%]). The rate of a second cSCC per 1000 person-years was 30.9 (95% CI, 30.2-31.6) in non-OTRs and 250.6 (95% CI, 232.2-270.1) in OTRs, with OTRs having a 4.3-fold increased rate in the adjusted analysis. The metastasis rate per 1000 person-years was 2.8 (95% CI, 2.6-3.0) in non-OTRs and 4.8 (95% CI, 3.4-6.7) in OTRs, with OTRs having a 1.5-fold increased rate in the adjusted analysis. A total of 30 451 deaths were observed, of which 29 895 (98.2%) were from causes other than cSCC. Death from cSCC was observed in 516 non-OTRs (1.1%) and 40 OTRs (3.3%). The rate of death from cSCC per 1000 person-years was 1.7 (95% CI, 1.5-1.8) in non-OTRs and 5.4 (95% CI, 3.9-7.4) in OTRs, with OTRs having a 5.5-fold increased rate in the adjusted analysis. CONCLUSIONS AND RELEVANCE: In this cohort study, OTRs with cSCC had significantly higher rates of second cSCC, metastasis, and death from cSCC than non-OTRs with cSCC, although most patients with cSCC in both groups died from causes other than cSCC. These findings are relevant for the planning of follow-up of patients with cSCC and for skin cancer services.
引用
- Gjersvik P, Falk RS, Roscher I, et al. Rates of Second Tumor, Metastasis, and Death From Cutaneous Squamous Cell Carcinoma in Patients With and Without Transplant-Associated Immunosuppression. JAMA Dermatol. 2023. PMID: 37466985. doi:10.1001/jamadermatol.2023.2029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。